Our top pick for
Building a portfolio
Precision BioSciences, Inc is a biotechnology business based in the US. Precision BioSciences shares (DTIL) are listed on the NASDAQ and all prices are listed in US Dollars. Precision BioSciences employs 231 staff and has a trailing 12-month revenue of around USD$24.3 million.
|52-week range||USD$4.55 - USD$16.6|
|50-day moving average||USD$10.9816|
|200-day moving average||USD$9.6441|
|Wall St. target price||USD$18.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.124|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$24.3 million|
|Gross profit TTM||USD$24.3 million|
|Return on assets TTM||-35.62%|
|Return on equity TTM||-119.3%|
|Market capitalisation||USD$504.6 million|
TTM: trailing 12 months
There are currently 3.5 million Precision BioSciences shares held short by investors – that's known as Precision BioSciences's "short interest". This figure is 2.5% up from 3.4 million last month.
There are a few different ways that this level of interest in shorting Precision BioSciences shares can be evaluated.
Precision BioSciences's "short interest ratio" (SIR) is the quantity of Precision BioSciences shares currently shorted divided by the average quantity of Precision BioSciences shares traded daily (recently around 851298.28431373). Precision BioSciences's SIR currently stands at 4.08. In other words for every 100,000 Precision BioSciences shares traded daily on the market, roughly 4080 shares are currently held short.
However Precision BioSciences's short interest can also be evaluated against the total number of Precision BioSciences shares, or, against the total number of tradable Precision BioSciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Precision BioSciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Precision BioSciences shares in existence, roughly 60 shares are currently held short) or 0.0684% of the tradable shares (for every 100,000 tradable Precision BioSciences shares, roughly 68 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Precision BioSciences.
Find out more about how you can short Precision BioSciences stock.
We're not expecting Precision BioSciences to pay a dividend over the next 12 months.
Over the last 12 months, Precision BioSciences's shares have ranged in value from as little as $4.55 up to $16.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Precision BioSciences's is 1.7948. This would suggest that Precision BioSciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic anti-CD19 CAR T cell product candidate for the patients with relapsed or refractory, or R/R, non-Hodgkin lymphoma, or NHL, or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; and PBCAR20A, that is in Phase 1/2a clinical trial, an allogeneic anti-CD20 CAR T therapy for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, which is in Phase 1/2a clinical trial, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products; and provides technology-centric solutions, Elo life systems, and Elo's technology platform solutions. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.